Melanotan I

Melanotan I (afamelanotide) is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH). It is FDA-approved as Scenesse for erythropoietic protoporphyria (EPP), a rare genetic disorder causing severe sun sensitivity.

Mechanism of Action

Binds to melanocortin 1 receptors (MC1R) on melanocytes, stimulating eumelanin production. This increases skin pigmentation and provides photoprotection without UV exposure.

Typical Dosage (Research)

Clinical: 16mg implant every 2 months. Research protocols for tanning typically use 0.5-1mg daily for loading, then maintenance dosing.

FDA-approved form is a subcutaneous implant. Research use involves subcutaneous injection. Often combined with minimal UV exposure to enhance results.

Side Effects & Risks

Nausea (especially initially), facial flushing, fatigue, headache, and darkening of existing moles or freckles.

May darken existing moles making melanoma detection difficult. Not recommended for those with history of melanoma. Long-term effects on melanocytes not fully characterized.

Who Uses Melanotan I

EPP patients (approved use), those seeking sunless tanning, fair-skinned individuals wanting photoprotection.